Home / Archive / May 2022

May 2022 Volume 18, Issue 5

Volume 18, Issue 5 | May 2022

May 2022

In this Issue

Immunology

Immune responses in young mice cause early T cell exhaustion against tumors

In children, T cells effectively combat acute infections such as COVID-19, but a new study in mice suggests that the T cell response is detrimental when fighting pediatric tumors.

Discover how immune response is dysregulated in autoimmune diseases.

Explained: How do autoimmune disorders arise?

At the frontline of an autoimmune attack are rogue immune cells turned foe against the body they were created to protect. Scientists study the complex etiology of autoimmune disorders to restore the broken balance.

Gene Therapy

A fluorescent image of an eye with the retina in dark blue and the BDNF receptor in light blue is shown against a black background.

Multiple mutations may no longer stump gene therapies

Creative solutions may enable gene therapy for more common diseases.

Illustration of hands using scissors and tweezers to cut and arrange strands of DNA.

A custom CRISPR solution

Engineered particles improve the efficiency of base editor delivery.

Editors Insight

Detective supplies including a hat, magnifying glass, map, aged paper, ink, and a writing quill sit on a wooden desk.

Scientific research is a series of infinite mysteries

Like detectives collecting evidence to solve a case, scientists perform experiments to unravel the mysteries of life.

Ophthamology

A collagen fiber floats in front of the retina in a close-up image of the eye, often called an eye floater.

Safer eye floater treatments come with a burst of nanobubbles

Between invasive surgery or risky laser therapy, people suffering from severe eye floaters have no great treatment options. Now, with the development of a safer and less invasive nanoparticle-based therapy, people with floaters may finally get their vision and quality of life back.

Prosthetics send messages between the eye and brain to help blind patients see

Bionic eyes: Treatments for blindness target the retina and the brain

Researchers are developing gene and cell therapies and prosthetics to help patients with blindness regain some vision. The first major prosthetic, the Argus II, was just discontinued. Where will the field go from here?